High-rolling investors have positioned themselves bullish on Novavax NVAX, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NVAX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Novavax. This is not a typical pattern.
The sentiment among these major traders is split, with 66% bullish and 0% bearish. Among all the options we identified, there was one put, amounting to $26,800, and 8 calls, totaling $574,056.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $2.5 to $20.0 for Novavax during the past quarter.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Novavax's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novavax's whale activity within a strike price range from $2.5 to $20.0 in the last 30 days.
Novavax 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVAX | CALL | SWEEP | BULLISH | 09/20/24 | $3.5 | $3.3 | $3.3 | $12.50 | $315.4K | 447 | 365 |
| NVAX | CALL | SWEEP | BULLISH | 09/20/24 | $3.25 | $3.2 | $3.2 | $12.50 | $65.9K | 447 | 0 |
| NVAX | CALL | TRADE | NEUTRAL | 09/20/24 | $5.0 | $4.75 | $4.88 | $10.00 | $38.0K | 1.4K | 0 |
| NVAX | CALL | SWEEP | BULLISH | 09/20/24 | $3.3 | $3.25 | $3.25 | $12.50 | $37.3K | 447 | 250 |
| NVAX | CALL | SWEEP | BULLISH | 08/09/24 | $3.6 | $3.35 | $3.6 | $11.00 | $36.0K | 106 | 0 |
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Following our analysis of the options activities associated with Novavax, we pivot to a closer look at the company's own performance.
Present Market Standing of Novavax
- Currently trading with a volume of 4,471,232, the NVAX's price is down by -6.72%, now at $13.96.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 18 days.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novavax options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
